412 related articles for article (PubMed ID: 25807298)
1. Discovery of a broad spectrum antiproliferative agent with selectivity for DDR1 kinase: cell line-based assay, kinase panel, molecular docking, and toxicity studies.
Elkamhawy A; Park JE; Cho NC; Sim T; Pae AN; Roh EJ
J Enzyme Inhib Med Chem; 2016; 31(1):158-66. PubMed ID: 25807298
[TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of new RAF kinase-inhibiting antiproliferative quinoline derivatives. Part 2: Diarylurea derivatives.
El-Gamal MI; Khan MA; Tarazi H; Abdel-Maksoud MS; Gamal El-Din MM; Yoo KH; Oh CH
Eur J Med Chem; 2017 Feb; 127():413-423. PubMed ID: 28088086
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 4-amino-1H-pyrazolo[3,4-d]pyrimidin derivatives as novel discoidin domain receptor 1 (DDR1) inhibitors.
Dong R; Zhou X; Wang M; Li W; Zhang JY; Zheng X; Tang KX; Sun LP
Bioorg Med Chem; 2021 Jan; 29():115876. PubMed ID: 33246255
[TBL] [Abstract][Full Text] [Related]
4. Discovery of potent and selective cytotoxic activity of new quinazoline-ureas against TMZ-resistant glioblastoma multiforme (GBM).
Elkamhawy A; Viswanath AN; Pae AN; Kim HY; Heo JC; Park WK; Lee CO; Yang H; Kim KH; Nam DH; Seol HJ; Cho H; Roh EJ
Eur J Med Chem; 2015 Oct; 103():210-22. PubMed ID: 26355532
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of new potent anticancer benzothiazole amides and ureas featuring pyridylamide moiety and possessing dual B-Raf(V600E) and C-Raf kinase inhibitory activities.
El-Damasy AK; Lee JH; Seo SH; Cho NC; Pae AN; Keum G
Eur J Med Chem; 2016 Jun; 115():201-16. PubMed ID: 27017549
[TBL] [Abstract][Full Text] [Related]
6. Novel promising 4-anilinoquinazoline-based derivatives as multi-target RTKs inhibitors: Design, molecular docking, synthesis, and antitumor activities in vitro and vivo.
Xu P; Chu J; Li Y; Wang Y; He Y; Qi C; Chang J
Bioorg Med Chem; 2019 Oct; 27(20):114938. PubMed ID: 31488358
[TBL] [Abstract][Full Text] [Related]
7. Discovery of 6-substituted 4-anilinoquinazolines with dioxygenated rings as novel EGFR tyrosine kinase inhibitors.
Li DD; Fang F; Li JR; Du QR; Sun J; Gong HB; Zhu HL
Bioorg Med Chem Lett; 2012 Sep; 22(18):5870-5. PubMed ID: 22901387
[TBL] [Abstract][Full Text] [Related]
8. Quinazoline-based multi-tyrosine kinase inhibitors: synthesis, modeling, antitumor and antiangiogenic properties.
Conconi MT; Marzaro G; Urbani L; Zanusso I; Di Liddo R; Castagliuolo I; Brun P; Tonus F; Ferrarese A; Guiotto A; Chilin A
Eur J Med Chem; 2013 Sep; 67():373-83. PubMed ID: 23900004
[TBL] [Abstract][Full Text] [Related]
9. Novel morpholin-3-one fused quinazoline derivatives as EGFR tyrosine kinase inhibitors.
Qin X; Lv Y; Liu P; Li Z; Hu L; Zeng C; Yang L
Bioorg Med Chem Lett; 2016 Mar; 26(6):1571-1575. PubMed ID: 26879314
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, in-vitro antiproliferative activity and kinase profile of new picolinamide based 2-amido and ureido quinoline derivatives.
El-Damasy AK; Seo SH; Cho NC; Kang SB; Pae AN; Kim KS; Keum G
Eur J Med Chem; 2015 Aug; 101():754-68. PubMed ID: 26218653
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, anticancer activity, toxicity evaluation and molecular docking studies of novel phenylaminopyrimidine-(thio)urea hybrids as potential kinase inhibitors.
Türe A; Kahraman DC; Cetin-Atalay R; Helvacıoğlu S; Charehsaz M; Küçükgüzel İ
Comput Biol Chem; 2019 Feb; 78():227-241. PubMed ID: 30579980
[TBL] [Abstract][Full Text] [Related]
12. Targeting EGFR/HER2 tyrosine kinases with a new potent series of 6-substituted 4-anilinoquinazoline hybrids: Design, synthesis, kinase assay, cell-based assay, and molecular docking.
Elkamhawy A; Farag AK; Viswanath AN; Bedair TM; Leem DG; Lee KT; Pae AN; Roh EJ
Bioorg Med Chem Lett; 2015 Nov; 25(22):5147-54. PubMed ID: 26475520
[TBL] [Abstract][Full Text] [Related]
13. Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: Design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro.
Chang J; Ren H; Zhao M; Chong Y; Zhao W; He Y; Zhao Y; Zhang H; Qi C
Eur J Med Chem; 2017 Sep; 138():669-688. PubMed ID: 28711702
[TBL] [Abstract][Full Text] [Related]
14. Discovery of nitroaryl urea derivatives with antiproliferative properties.
Wróbel TM; Kiełbus M; Kaczor AA; Kryštof V; Karczmarzyk Z; Wysocki W; Fruziński A; Król SK; Grabarska A; Stepulak A; Matosiuk D
J Enzyme Inhib Med Chem; 2016 Aug; 31(4):608-18. PubMed ID: 26114307
[TBL] [Abstract][Full Text] [Related]
15. Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor.
Kim HG; Tan L; Weisberg EL; Liu F; Canning P; Choi HG; Ezell SA; Wu H; Zhao Z; Wang J; Mandinova A; Griffin JD; Bullock AN; Liu Q; Lee SW; Gray NS
ACS Chem Biol; 2013 Oct; 8(10):2145-50. PubMed ID: 23899692
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, Molecular Modeling and Biological Evaluation of 4-Alkoxyquinazoline Derivatives as Novel Inhibitors of VEGFR2.
Lu L; Zhao TT; Liu TB; Sun WX; Xu C; Li DD; Zhu HL
Chem Pharm Bull (Tokyo); 2016 Nov; 64(11):1570-1575. PubMed ID: 27568484
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of novel dasatinib analogues as potent DDR1 and DDR2 kinase inhibitors.
Liu L; Hussain M; Luo J; Duan A; Chen C; Tu Z; Zhang J
Chem Biol Drug Des; 2017 Mar; 89(3):420-427. PubMed ID: 27589335
[TBL] [Abstract][Full Text] [Related]
18. Discovery of (7-aryl-1,5-naphthyridin-2-yl)ureas as dual inhibitors of ERK2 and Aurora B kinases with antiproliferative activity against cancer cells.
Defaux J; Antoine M; Logé C; Le Borgne M; Schuster T; Seipelt I; Aicher B; Teifel M; Günther E; Gerlach M; Marchand P
Bioorg Med Chem Lett; 2014 Aug; 24(16):3748-52. PubMed ID: 25022204
[TBL] [Abstract][Full Text] [Related]
19. Combination of 4-anilinoquinazoline, arylurea and tertiary amine moiety to discover novel anticancer agents.
Zuo SJ; Zhang S; Mao S; Xie XX; Xiao X; Xin MH; Xuan W; He YY; Cao YX; Zhang SQ
Bioorg Med Chem; 2016 Jan; 24(2):179-90. PubMed ID: 26706113
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, broad-spectrum antiproliferative activity, and kinase inhibitory effect of triarylpyrazole derivatives possessing arylamides or arylureas moieties.
Gamal El-Din MM; El-Gamal MI; Abdel-Maksoud MS; Yoo KH; Oh CH
Eur J Med Chem; 2016 Aug; 119():122-31. PubMed ID: 27155467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]